JP2019532026A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532026A5 JP2019532026A5 JP2019508935A JP2019508935A JP2019532026A5 JP 2019532026 A5 JP2019532026 A5 JP 2019532026A5 JP 2019508935 A JP2019508935 A JP 2019508935A JP 2019508935 A JP2019508935 A JP 2019508935A JP 2019532026 A5 JP2019532026 A5 JP 2019532026A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tamoxifen
- serm
- subject
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 68
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 36
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 36
- 229960001603 tamoxifen Drugs 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 201000007737 Retinal degeneration Diseases 0.000 claims description 7
- 229960004622 raloxifene Drugs 0.000 claims description 7
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 7
- 230000004258 retinal degeneration Effects 0.000 claims description 7
- 108091008695 photoreceptors Proteins 0.000 claims description 6
- -1 afimoxifen Chemical compound 0.000 claims description 4
- 229960000817 bazedoxifene Drugs 0.000 claims description 4
- UCJGJABZCDBEDK-UHFFFAOYSA-N bazedoxifene Chemical compound C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 UCJGJABZCDBEDK-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000008069 Geographic Atrophy Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 229950005529 arzoxifene Drugs 0.000 claims description 3
- MCGDSOGUHLTADD-UHFFFAOYSA-N arzoxifene Chemical compound C1=CC(OC)=CC=C1C1=C(OC=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 MCGDSOGUHLTADD-UHFFFAOYSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims description 3
- 210000000274 microglia Anatomy 0.000 claims description 3
- 230000000770 proinflammatory effect Effects 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 230000004382 visual function Effects 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 230000007850 degeneration Effects 0.000 claims description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004304 visual acuity Effects 0.000 claims 1
- 241000282412 Homo Species 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377439P | 2016-08-19 | 2016-08-19 | |
| US62/377,439 | 2016-08-19 | ||
| PCT/US2017/046359 WO2018034945A1 (en) | 2016-08-19 | 2017-08-10 | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019532026A JP2019532026A (ja) | 2019-11-07 |
| JP2019532026A5 true JP2019532026A5 (https=) | 2020-08-13 |
| JP7100019B2 JP7100019B2 (ja) | 2022-07-12 |
Family
ID=59702849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508935A Active JP7100019B2 (ja) | 2016-08-19 | 2017-08-10 | 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11040019B2 (https=) |
| EP (1) | EP3484463B1 (https=) |
| JP (1) | JP7100019B2 (https=) |
| AU (1) | AU2017312499B2 (https=) |
| WO (1) | WO2018034945A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3743922A1 (en) * | 2018-01-25 | 2020-12-02 | Per Hall | Compositions and methods for monitoring the treatment of breast disorders |
| CN108295055B (zh) * | 2018-02-26 | 2019-11-05 | 王晓琳 | 他莫昔芬在制备保护视网膜感光细胞的药物中的应用 |
| JP2020174859A (ja) * | 2019-04-17 | 2020-10-29 | 学校法人日本医科大学 | 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法 |
| JP7392219B2 (ja) * | 2020-01-20 | 2023-12-06 | 株式会社萌芽プランツ | フラボノイド組成物 |
| GB202000926D0 (en) * | 2020-01-22 | 2020-03-04 | Ucl Business Ltd | Method of diagnosis |
| US12115005B2 (en) * | 2020-03-26 | 2024-10-15 | Diamentis Inc. | Systems and methods for processing retinal signal data and identifying conditions |
| AU2023219254A1 (en) | 2022-02-09 | 2024-08-01 | Diamentis Inc. | Systems and methods for retinal stimulation and/or collecting retinal signal data |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (https=) | 1962-09-13 | |||
| FR2558373B1 (fr) | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
| US4852579A (en) | 1987-04-20 | 1989-08-01 | Karl Storz Endoscopy Gmbh And Company | Photocharacterization and treatment of normal abnormal and ectopic endometrium |
| JP2918991B2 (ja) | 1990-05-25 | 1999-07-12 | 三菱瓦斯化学株式会社 | 漂白洗浄剤組成物 |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| CA2223595C (en) * | 1995-06-07 | 2008-08-05 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| CA2280181A1 (en) * | 1997-02-09 | 1998-08-13 | Pharmos Corporation | Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones |
| DE19718826A1 (de) | 1997-05-05 | 1998-11-12 | Marion S Dr Eckmiller | Verwendung biologisch aktiver Wirkstoffe zum Beeinflussen des Extrazellulär-Raumes von Sinneszellen und Verfahren zur Wirkstoff-Administrationssteuerung |
| US6759050B1 (en) | 1998-12-03 | 2004-07-06 | Avigen, Inc. | Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| CA2383499C (en) | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| US6416777B1 (en) | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| WO2002002099A1 (en) | 2000-07-05 | 2002-01-10 | Astrazeneca Ab | Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition |
| DE60106293T2 (de) | 2000-10-25 | 2005-11-17 | Eli Lilly And Co., Indianapolis | Verfahren zur inhibierung von katarakten |
| EP1339438B1 (en) | 2000-11-29 | 2005-10-19 | Allergan Inc. | Preventing transplant rejection in the eye |
| US20030032676A1 (en) | 2001-08-09 | 2003-02-13 | Kimelberg Harold K. | Drugs for treatment of cerebral injury and methods of use thereof |
| JP4684655B2 (ja) | 2002-12-18 | 2011-05-18 | ラボラトワール ブザン アンテルナスィヨナル | ４−ヒドロキシタモキシフェンによる乳房密度低下 |
| US20050244461A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
| EP1647271A1 (en) | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
| WO2006040839A1 (ja) * | 2004-10-15 | 2006-04-20 | Advanced Medicine Research Institute | 眼疾患処置用点眼剤及びキット |
| EA201500845A1 (ru) | 2005-11-28 | 2016-04-29 | Джи Ти Икс, ИНК. | Агенты, связывающиеся с ядерными рецепторами |
| US20130338145A1 (en) | 2006-10-03 | 2013-12-19 | Claire H. Mitchell | Method for Mediating Dopamine Receptor-Driven Reacidification of Lysosomal pH |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2011113904A1 (en) * | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| EA026675B1 (ru) * | 2010-06-16 | 2017-05-31 | Эндорешерш, Инк. | Способы лечения или предотвращения эстрогензависимых заболеваний |
| EP2554662A1 (en) * | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| CN103211803A (zh) | 2013-04-02 | 2013-07-24 | 苏州大学附属第一医院 | 他莫昔芬在治疗蛛网膜下腔出血后发生的早期脑损伤的应用 |
| US9896466B2 (en) | 2013-04-24 | 2018-02-20 | Kkcg Ag | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level |
| WO2016064959A1 (en) | 2014-10-21 | 2016-04-28 | Odin Biotech | Two-layer ocular implant comprising a tyrosine kinase inhibitor |
-
2017
- 2017-08-10 AU AU2017312499A patent/AU2017312499B2/en active Active
- 2017-08-10 US US16/325,678 patent/US11040019B2/en active Active
- 2017-08-10 WO PCT/US2017/046359 patent/WO2018034945A1/en not_active Ceased
- 2017-08-10 EP EP17757972.9A patent/EP3484463B1/en active Active
- 2017-08-10 JP JP2019508935A patent/JP7100019B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532026A5 (https=) | ||
| CN101820878B (zh) | 用于治疗创伤后应激障碍的四氢喹啉衍生物 | |
| DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
| JP2003095979A (ja) | ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置 | |
| RU2011134499A (ru) | Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона | |
| JP2015512406A5 (https=) | ||
| JP2019530713A5 (https=) | ||
| JP2019517511A5 (https=) | ||
| JP2021535107A5 (https=) | ||
| JP2015532296A5 (https=) | ||
| JP2024513581A (ja) | 本態性振戦の治療 | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| TW201002325A (en) | Pharmaceutical compositions for treating schizophrenia | |
| IL272893B1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease | |
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| James et al. | Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis | |
| JP2018518460A5 (https=) | ||
| MX2020007948A (es) | Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. | |
| JP2024503727A5 (https=) | ||
| CN104173332B (zh) | 银杏内酯类化合物的用途 | |
| JP2020536121A5 (https=) | ||
| JP2018506533A5 (https=) | ||
| Schmidt et al. | Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs | |
| Nomoto et al. | A case of frontotemporal dementia with sexual disinhibition controlled by aripiprazole. | |
| JP2007517885A5 (https=) |